16 0

In amongst the abstruse speculation about the length of the Brexit transition period, how the facilitated customs arrangement might work and the true meaning of the “backstop” at the Irish border, sometimes it is worth reminding ourselves of the concrete, real and immediate risks to the UK of leaving the European Union. One such risk is whether we will have a reliable supply of up-to-date medicines and drugs, both in the short and the long term, after Brexit; few issues highlight the short- and long-term costs of leaving the EU more graphically and more personally. The European Medicines Agency is being transferred from London to Amsterdam, and with it the bulk of the expertise in testing... Full story

18 October